CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Recruiting in Palo Alto (17 mi)
+11 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This is a phase II, open-label, single-arm, multicenter study to assess the efficacy and safety of JWCAR029 in adult R/R Mantle Cell Lymphoma subjects in China.
Research Team
Eligibility Criteria
Inclusion Criteria
≥ 18 years old;
Sign on the informed consent;
Subject must have histologically confirmed mantle cell lymphoma;
See 7 more
Treatment Details
Interventions
- JWCAR029 (CAR T-cell Therapy)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: JWCAR029 treatmentExperimental Treatment1 Intervention
JWCAR029 be administrated at dose level: 1 x 10\^8 CAR+T cells
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Loading ...
Who Is Running the Clinical Trial?
Shanghai Ming Ju Biotechnology Co., Ltd.
Lead Sponsor
Trials
17
Patients Recruited
730+